PWE-119 Iron isomaltoside to improve oesophagogastric adenocarcinoma related anaemia and quality of life during chemotherapy

Oliver Ng(Nottingham University Hospitals NHS Trust), Austin G. Acheson(Nottingham University Hospitals NHS Trust), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Barrie Keeler(Nottingham University Hospitals NHS Trust), John Simpson(Nottingham University Hospitals NHS Trust), Matthew Brookes(Wolverhampton Hospital)

Unknown

June 1, 2018

10.1136/gutjnl-2018-bsgabstracts.353

Cited by 1

Related Papers

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

|New England Journal of Medicine|2010|4.5k

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

|The Lancet|2022|664

Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial

|The Lancet Oncology|2013|605

Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial

|The Lancet Oncology|2014|374

Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial

|The Lancet Oncology|2015|282